breakyl 800 mikrogrami aiz vaiga lietojamās membrānas
meda pharma gmbh & co.kg, germany - fentanils - aiz vaiga lietojamā membrāna - 800 mikrogrami
breakyl 200 mikrogrami aiz vaiga lietojamās membrānas
meda pharma gmbh & co.kg, germany - fentanils - aiz vaiga lietojamā membrāna - 200 mikrogrami
breakyl 400 mikrogrami aiz vaiga lietojamās membrānas
meda pharma gmbh & co.kg, germany - fentanils - aiz vaiga lietojamā membrāna - 400 mikrogrami
breakyl 600 mikrogrami aiz vaiga lietojamās membrānas
meda pharma gmbh & co.kg, germany - fentanils - aiz vaiga lietojamā membrāna - 600 mikrogrami
breakyl 1200 mikrogrami aiz vaiga lietojamās membrānas
meda pharma gmbh & co.kg, germany - fentanils - aiz vaiga lietojamā membrāna - 1200 mikrogrami
grafalon 20 mg/ml koncentrāts infūziju šķīduma pagatavošanai
neovii biotech gmbh, germany - imūbnglobulīns pret cilvēka t limfocītiem, dzīvnieka - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml
lunsumio
roche registration gmbh - mosunetuzumab - limfoma, folikulāra - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
giotrif
boehringer ingelheim international gmbh - afatinib - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - giotrif kā monotherapy ir indicēts, lai ārstētu ofepidermal augšanas faktora receptoru (egfr) tki-naivs pieaugušiem pacientiem ar lokāli papildu vai metastātiska nav maza šūnu plaušu vēzis (nsclc) ar aktivizējot egfr mutācijas(s);vietas papildu vai metastātiska nsclc no plakanšūnu histoloģija virzās uz vai pēc platīna ķīmijterapiju.
venclyxto
abbvie deutschland gmbh co. kg - venetoklakss - leikēmija, limfocītu, hroniska, b-šūna - antineoplastiski līdzekļi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
clindamycin-mip 300 mg apvalkotās tabletes
mip pharma gmbh, germany - klindamicīns - apvalkotā tablete - 300 mg